Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cardinal Health Inc    CAH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cardinal Health to Buy Medical-Supplies Provider AssuraMed for $2.07 Billion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2013 | 02:08pm CEST
   By Melodie Warner 
 

Cardinal Health Inc. (>> Cardinal Health, Inc.) agreed to acquire closely held medical-supplies provider AssuraMed for $2.07 billion as the drug wholesaler looks to diversify its offerings.

AssuraMed currently serves more than one million patients nationally with more than 30,000 products. The company bought Invacare Corp.'s (>> Invacare Corporation) domestic medical supplies business for $150 million last month. Including that business, Cardinal Heath said AssuraMed had 2012 revenue of $1 billion.

After the transaction is complete, Cardinal Health will supply ostomy, diabetes, insulin therapy, urological, wound care and incontinence products to the home-healthcare market.

"This is a platform opportunity for Cardinal Health products and services which will be increasingly important as the delivery of care migrates to more cost-effective settings," said Chairman and Chief Executive George Barrett.

Cardinal Health expects AssuraMed to add two cents to three cents a share to its fiscal 2013 adjusted earnings, assuming the deal closes by early April.

The company also estimates its will boost fiscal 2014 adjusted earnings by at least 18 cents a share.

Cardinal has previously disclosed the loss of its contract with pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) to rival AmerisourceBergen Corp. (>> AmerisourceBergen Corp.). Two of Cardinal's huge drug-distribution customers, Walgreen Co. (>> Walgreen Company) and CVS Caremark Corp. (>> CVS Caremark Corporation), have contracts set to end this summer.

The company earlier this month reported its fiscal second-quarter earnings rose 16% as improved margins helped to offset weaker revenue at its pharmaceutical division, which was caused partly by generic-drug introductions.

Shares closed Wednesday at $45.44 and were inactive premarket. The stock has risen 8% over the past year.

Write to Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDINAL HEALTH INC
03:04a SHANGHAI PHARMACEUTICALS : SH Pharma confirms bids for Cardinal's PRC business
10/19 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Entry into a Material Defini..
10/18 CARDINAL HEALTH : Mike's Musings – Drug Companies, Doctors Must Do The Righ..
10/17 CATALENT : Clinical Supply Appoints New General Manager at Bathgate, Scotland Fa..
10/17 CARDINAL HEALTH : to Webcast Discussion of First-Quarter Results for Fiscal Year..
10/17 CARDINAL HEALTH : NCPA Releases 2017 Digest
10/14 Opioid lawsuit expanded to include manufacturers
10/12 VALERITAS : Wins Fourth Consecutive Cardinal Health Supply Chain Excellence Awar..
10/11 CARDINAL HEALTH : $574,714 Federal Contract Awarded to Cardinal Health
10/05 CARDINAL HEALTH : Studies from Cardinal Health Reveal New Findings on Lymphoma (..
More news
News from SeekingAlpha
10/18 California looking to pull Cardinal Health license over opioids - Stat News
10/16 Bert's October Dividend Stock Watch List
10/15 WEEK IN REVIEW : Shanghai Pharma Bids In Cardinal China's $1.5 Billion Auction
10/13 60 Minutes report-stocked selloff in drug distributors overblown - Cowen
10/13 60 Minutes to run piece on opioid epidemic critical of suppliers this Sunday;..
Financials ($)
Sales 2018 137 B
EBIT 2018 2 783 M
Net income 2018 1 342 M
Debt 2018 7 735 M
Yield 2018 2,86%
P/E ratio 2018 16,48
P/E ratio 2019 14,32
EV / Sales 2018 0,21x
EV / Sales 2019 0,20x
Capitalization 20 394 M
Chart CARDINAL HEALTH INC
Duration : Period :
Cardinal Health Inc Technical Analysis Chart | CAH | US14149Y1082 | 4-Traders
Technical analysis trends CARDINAL HEALTH INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 72,4 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
George S. Barrett Chairman & Chief Executive Officer
Michael C. Kaufmann Chief Financial Officer
Patricia B. Morrison Chief Information Officer & Executive VP
Calvin Ramarro Darden Independent Director
Gregory B. Kenny Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARDINAL HEALTH INC-10.10%20 394
CVS HEALTH-5.42%75 327
WALGREENS BOOTS ALLIANCE-18.15%72 488
EXPRESS SCRIPTS HOLDING CO-16.02%33 365
MCKESSON CORPORATION6.77%30 742
AMERISOURCEBERGEN CORP.5.13%17 636